Skip to Content
Austin  Kirschner

Austin Kirschner, M.D., Ph.D.

Assistant Professor of Radiation Oncology
Assistant Professor of Cancer Biology

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Gateway-Vanderbilt Cancer Treatment Center
    (931) 221-0479

    Vanderbilt-Ingram Cancer Center Radiation Oncology
    (615) 322-2555

  • Faxes
    Gateway-Vanderbilt Cancer Treatment Center Fax
    (931) 221-3280
    Vanderbilt-Ingram Cancer Center Radiation Oncology Fax
    (615) 343-3075

    Clinic Fax
  • Addresses
    The Vanderbilt Clinic (TVC)-Preston Research Building
    Department of Radiation Oncology, B1003
    Nashville, TN 37232-5671

    Gateway-Vanderbilt Cancer Treatment Center
    375 Alfred Thun Road
    Clarksville, TN 37040

    Vanderbilt-Ingram Cancer Center Radiation Oncology
    22nd at Pierce Avenue, B1034
    Nashville, TN 37232-5671

    2220 Pierce Ave, B944 TVC
    Nashville, TN 37232

I am a physician in the department of radiation oncology. I treat several types of malignancies including genitourinary, pediatrics, lymphoma, leukemia, and cutaneous malignancies.

I also have research interests that involve the study of cancer biology with focus on developing new cancer treatments and improving therapies that are currently used. I focus on targeted cancer treatment as well as the combination of drug therapy with radiation therapy to enhance its effectiveness, while limiting toxicity and side effects. Ultimately, my goal is to translate my research findings into clinical trials.

Research Interests
  Prostate Cancer
  Development of Radiation Sensitizing Drugs
  Investigation of Cancer Treatment-Resistance Mechanisms

Clinical Interests
  Lymphoma / Leukemia
  Genitourinary Malignancies
  Tremor Treatment by Stereotactic Radiosurgery

  Honors Scholar, New York University
  Isidore Rubiner Award for Chemistry, New York University
  NASA Graduate Student Research Program Fellowship Grant, New York University
  Medical Scientist Training Program, Northwestern University
  Biotechnology Training Program, Northwestern University
  ABR Leonard B. Holman Research Pathway, Vanderbilt University
  RSNA Roentgen Resident/Fellow Research Award, Vanderbilt University
  American Brachytherapy Society HDR Brachytherapy Scholarship, Sunnybrook Odette Cancer Center, Toronto, CA

  • Bachelor's of Arts - New York University, NY, NY
  • Doctor of Medicine (M.D.) - Northwestern University Feinberg School of Medicine, Chicago, IL
  • Doctor of Philosophy (Ph.D.) - Northwestern University, Evanston, IL
  • Internship - Northshore University Healthsystem, Evanston, IL (Affiliate of University of Chicago)
  • Residency - Vanderbilt University School of Medicine, Nashville, TN
Research Description

My central theme of research is cancer biology with focus on developing new cancer treatments, especially for locally advanced and metastatic cancers that have limited treatments. I believe new cancer therapies should be targeted to specific cancer pathways to limit their toxicity and side effects, while providing effective treatment. I am a physician-scientist treating cancer patients in a department of radiation oncology and perform basic science and translational research investigating new cancer therapies and mechanisms. Ultimately, my goal is to directly translate my research findings into clinical trials with patients.

My current research focuses on prostate cancer, since there is a significant clinical deficit: nearly 30,000 men die from prostate cancer each year in the USA, making it the #2 cause of cancer death in men (world-wide: 1.1 million diagnosed and 307,000 deaths).

One research project studies a core mechanism in prostate cancer involving the oncogene PIM1 kinase, which has been implicated in numerous human malignancies, making it an important drug target for directed cancer therapy. I pursue research work that reveals PIM1-related mechanistic details in prostate cancer and demonstrates the efficacy of PIM1-directed inhibition for the treatment of prostate cancer.

Another research project focuses on resistance to current cancer-directed therapies. Drugs that improve the effectiveness hormone therapy (androgen deprivation therapy), radiation therapy, and chemotherapy are needed to treat localized high-risk and metastatic disease. I study detailed mechanisms of the androgen receptor pathway, the DNA-damage repair pathway, and other pathways toward developing new therapeutic agents.

  • Luo G, Neimat JS, Cmelak A, Kirschner AN, Attia A, Morales-Paliza M, Ding GX. Margin of error for a frameless image guided radiosurgery system: Direct confirmation based on posttreatment MRI scans. Pract Radiat Oncol [print-electronic]. 2017 May; 7(3): e223-e231. PMID: 27720703, PII: S1879-8500(16)30156-4, DOI: 10.1016/j.prro.2016.08.006, ISSN: 1879-8519.
    Available from:
  • Patel CG, Ding G, Kirschner A. Scalp-sparing total skin electron therapy in mycosis fungoides: Case report featuring a technique without lead. Pract Radiat Oncol [print-electronic]. 2017 Mar 3/27/2017; PMID: 28438420, PII: S1879-8500(17)30070-X, DOI: 10.1016/j.prro.2017.03.009, ISSN: 1879-8519.
    Available from:
  • Allen JC, Kirschner A, Scarpato KR, Morgans AK. Current Management of Refractory Germ Cell Tumors and Future Directions. Curr Oncol Rep. 2017 Feb; 19(2): 8. PMID: 28220447, PII: 10.1007/s11912-017-0572-y, DOI: 10.1007/s11912-017-0572-y, ISSN: 1534-6269.
    Available from:
  • Isaacs D, Cmelak A, Kirschner AN, Phibbs F. Radiotherapy-induced hemichorea. Neurology [print-electronic]. 2016 Apr 4/5/2016; 86(14): 1355-7. PMID: 26944270, PII: WNL.0000000000002546, DOI: 10.1212/WNL.0000000000002546, ISSN: 1526-632X.
    Available from:
  • Isaacs D, Cmelak A, Kirschner AN, Phibbs F. Radiotherapy-induced hemichorea. Neurology [print-electronic]. 2016 Apr 4/5/2016; 86(14): 1355-7. PMID: 26944270, PII: WNL.0000000000002546, DOI: 10.1212/WNL.0000000000002546, ISSN: 1526-632X.
    Available from:
  • Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl. Cancer Inst [electronic-print]. 2015 Feb; 107(2): PMID: 25505253, PMCID: PMC4326311, PII: dju407, DOI: 10.1093/jnci/dju407, ISSN: 1460-2105.
    Available from:
  • Kirschner AN, Sathiaseelan V, Zhang Y, David J, Kalapurakal JA. Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base. J Contemp Brachytherapy [print-electronic]. 2014 Mar; 6(1): 33-9. PMID: 24790620, PMCID: PMC4003430, PII: 22582, DOI: 10.5114/jcb.2014.42023, ISSN: 1689-832X.
    Available from:
  • Kirschner AN, Kidd EA, Dewees T, Perkins SM. Treatment approach and outcomes of vaginal melanoma. Int. J. Gynecol. Cancer. 2013 Oct; 23(8): 1484-9. PMID: 23945202, DOI: 10.1097/IGC.0b013e3182a1ced8, ISSN: 1525-1438.
    Available from:
  • Shinohara ET, Mitra N, Fei W, Kirschner AN, Metz JM. Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancer. Am. J. Clin. Oncol. 2012 Dec; 35(6): 543-8. PMID: 21926898, DOI: 10.1097/COC.0b013e31822dfd3c, ISSN: 1537-453X.
    Available from:
  • Kirschner AN, Kuhlmann E, Kuzniar TJ. Eosinophilic pleural effusion complicating allergic bronchopulmonary aspergillosis. Respiration [print-electronic]. 2011; 82(5): 478-81. PMID: 21311176, PII: 000323617, DOI: 10.1159/000323617, ISSN: 1423-0356.
    Available from:
  • Matsuura H, Kirschner AN, Longnecker R, Jardetzky TS. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2010 Dec 12/28/2010; 107(52): 22641-6. PMID: 21149717, PMCID: PMC3012493, PII: 1011806108, DOI: 10.1073/pnas.1011806108, ISSN: 1091-6490.
    Available from:
  • Liu F, Marquardt G, Kirschner AN, Longnecker R, Jardetzky TS. Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays. J. Virol [print-electronic]. 2010 Oct; 84(19): 10375-85. PMID: 20668073, PMCID: PMC2937788, PII: JVI.00381-10, DOI: 10.1128/JVI.00381-10, ISSN: 1098-5514.
    Available from:
  • Shaw PL, Kirschner AN, Jardetzky TS, Longnecker R. Characteristics of Epstein-Barr virus envelope protein gp42. Virus Genes [print-electronic]. 2010 Jun; 40(3): 307-19. PMID: 20162447, PMCID: PMC2854865, DOI: 10.1007/s11262-010-0455-x, ISSN: 1572-994X.
    Available from:
  • Kirschner AN, Sorem J, Longnecker R, Jardetzky TS. Structure of Epstein-Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry. Structure. 2009 Feb 2/13/2009; 17(2): 223-33. PMID: 19217393, PMCID: PMC3085316, PII: S0969-2126(09)00025-2, DOI: 10.1016/j.str.2008.12.010, ISSN: 0969-2126.
    Available from:
  • Kirschner AN, Lowrey AS, Longnecker R, Jardetzky TS. Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. J. Virol [print-electronic]. 2007 Sep; 81(17): 9216-29. PMID: 17581996, PMCID: PMC1951443, PII: JVI.00575-07, DOI: 10.1128/JVI.00575-07, ISSN: 0022-538X.
    Available from:
  • Kirschner AN, Omerovic J, Popov B, Longnecker R, Jardetzky TS. Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J. Virol. 2006 Oct; 80(19): 9444-54. PMID: 16973550, PMCID: PMC1617263, PII: 80/19/9444, DOI: 10.1128/JVI.00572-06, ISSN: 0022-538X.
    Available from:
  • Braden BC, Goldbaum FA, Chen BX, Kirschner AN, Wilson SR, Erlanger BF. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Proc. Natl. Acad. Sci. U.S.A. 2000 Oct 10/24/2000; 97(22): 12193-7. PMID: 11035793, PMCID: PMC17317, PII: 210396197, DOI: 10.1073/pnas.210396197, ISSN: 0027-8424.
    Available from: